OR WAIT null SECS
Forecyte Bio has opened a new GMP facility in Shanghai just two months after its sister site in the United States.
Forecyte Bio held an opening ceremony on March 31, 2023, for its new cell and gene therapy good manufacturing practice (GMP) facility in Shanghai, China, following the successful opening of its United States facility in January 2023. The new Shanghai facility totals 140,000 ft2 with a total investment of nearly $40 million. It offers multiple GMP production lines for plasmids, viral vectors, and cell therapies.
The dual sites in the US and China offer advantages to cell and gene therapy (CGT) companies, as both facilities offer high-quality production capacities and an executive team experienced in CGT chemistry, manufacturing, and controls manufacturing. Forcyte Bio’s goal is to help its customers accelerate their product development process from R&D to clinic and to market. The company also enables CGT products to be manufactured and filed in multiple nations.
"The CGT industry has entered a stage of rapid development,” said Yingke He, founder and CEO of Forecyte Bio, during the opening ceremony. “With the opening of the Shanghai production and R&D center, the manufacturing capacity of Forecyte Bio in China and the United States are ready to serve its customers from US, China, and around the globe. Thanks to the trust and support from our landlord, our customers, and investors, and mostly our hardworking employees, we have been able to reach today's achievement in such a short time."
Source: Forecyte Bio